具有潜在的多目标抑制性质的抗质4-piperidone-1-phosphonothioates具有潜在的多目标抑制性质
Mohamed S Bekheit1, Siva S Panda2, Benson M Kariuki3
1Department of Pesticide Chemistry, National Research Centre, Dokki, 12622, Giza, Egypt.
Scientific reports
|November 18, 2025
概括
新的酸化合物显示出强大的抗癌活性,在抗乳腺癌,结肠癌和皮肤癌细胞系方面表现优于现有的药物. 这些药物还抑制了与癌症相关的关键蛋白质,如MDM2和拓酶,这表明它们有可能成为多向癌症疗法.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症生物学 癌症生物学
背景情况:
- 开发新的抗癌药物对于克服耐药性和改善患者治疗结果至关重要.
- 皮皮里衍生物已被证明是抗癌药物发现的支架.
- 针对多个途径,如增殖和DNA修复,可能会提高治疗疗效.
研究的目的:
- 为了合成一个新的系列的3,5-bis(ylidene) -4-piperidone-1-phosphonothioates.
- 评估这些化合物对各种人类癌症细胞系的抗增殖活性.
- 调查其抗癌作用背后的生物化学机制,包括抑制MDM2和拓酶酶.
主要方法:
- 通过脱化合成3,5-bis(ylidene) -4-piperidone-1-phosphonothioates的合成方法.
- 针对MCF7,HCT116和A431癌细胞系的体外抗增殖试验.
- 生物化学试验以评估抑制MDM2,p53激活,多聚酶I和多聚酶IIα.
- 分子对接研究以合理化观察到的MDM2抑制活性.
主要成果:
- 合成的索酸类型的高产量得到了实现.
- 化合物20c对MCF7,HCT116和A431细胞表现出显著的抗增殖活性,超过了5-甲和苏尼替尼的抗增殖活性.
- 化合物20k显示MDM2的强烈抑制,超过了多克索鲁比辛.
- 化合物20i有效抑制了拓聚酶I和IIα,与标准药物相比.
- 分子对接研究支持观察到的MDM2抑制.
结论:
- 合成的3,5-bis(ylidene) -4-piperidone-1-phosphonothioates具有强大的抗癌特性.
- 这些化合物通过多种机制起作用,包括MDM2抑制和拓酶向.
- 最有效的类似物,如20c,20k和20i,是作为多向抗癌剂进一步开发的有希望的候选物.
相关概念视频
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
890
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
890
Antipsychotic Drugs: Typical and Atypical Agents
718
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
718
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
797
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
797
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
527

